Tejara Capital Ltd Has $7.13 Million Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Tejara Capital Ltd reduced its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 12.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,661,547 shares of the biotechnology company’s stock after selling 644,269 shares during the period. Heron Therapeutics comprises about 4.6% of Tejara Capital Ltd’s investment portfolio, making the stock its 8th biggest position. Tejara Capital Ltd owned 3.06% of Heron Therapeutics worth $7,132,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Congress Park Capital LLC raised its stake in shares of Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company’s stock worth $3,757,000 after acquiring an additional 477,417 shares during the last quarter. Clearline Capital LP raised its stake in shares of Heron Therapeutics by 48.9% in the third quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock worth $4,431,000 after acquiring an additional 731,246 shares during the last quarter. New York State Common Retirement Fund raised its stake in shares of Heron Therapeutics by 3.2% in the fourth quarter. New York State Common Retirement Fund now owns 1,321,006 shares of the biotechnology company’s stock worth $2,021,000 after acquiring an additional 41,062 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Heron Therapeutics by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company’s stock worth $1,692,000 after acquiring an additional 9,418 shares during the last quarter. Finally, CM Management LLC raised its stake in shares of Heron Therapeutics by 40.0% in the fourth quarter. CM Management LLC now owns 700,000 shares of the biotechnology company’s stock worth $1,071,000 after acquiring an additional 200,000 shares during the last quarter. 80.01% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on HRTX. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a research note on Friday, February 28th. StockNews.com downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 8th.

Heron Therapeutics Price Performance

HRTX opened at $2.39 on Tuesday. The company has a market cap of $364.07 million, a price-to-earnings ratio of -13.28 and a beta of 1.55. The firm has a 50 day simple moving average of $1.86 and a 200 day simple moving average of $1.74. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.05. The business had revenue of $40.78 million for the quarter, compared to the consensus estimate of $37.37 million. As a group, analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.